Table 1. Baseline characteristics.
| Variable | Overall | SS | DOT | p-value |
|---|---|---|---|---|
| n (%) | 145 (100) | 71 (49.0) | 74 (51.0) | |
| OST [n (%)] | 85 (58.6) | 11 (15.5) | 74 (100) | <0.0001 |
| HIV [n (%)] | 4 (2.8) | 2 (2.8) | 2 (2.7) | 1 |
| Sex [n (%)] | 0.056 | |||
| Male | 91 (62.8) | 39 (54.9) | 52 (70.3) | |
| Female | 54 (37.2) | 32 (45.1) | 22 (29.7) | |
| Age (years) [median (IQR)] | 41.1 (19.5) | 50.6 (20.3) | 38.7 (12.5) | <0.0001 |
| Fibrosis stagea [n (%)] | 0.792 | |||
| F0/F1 | 90 (62.1) | 44 (62.0) | 46 (62.2) | |
| F2 | 34 (23.4) | 15 (21.1) | 19 (25.7) | |
| F3 | 15 (10.3) | 8 (11.3) | 7 (9.5) | |
| F4 | 6 (4.1) | 4 (5.6) | 2 (2.7) | |
| HCV genotype [n (%)] | 0.313 | |||
| 1b | 82 (56.6) | 40 (56.3) | 42 (56.8) | |
| - 1a | 57 (39.3) | 22 (31.0) | 35 (47.3) | |
| - 1b | 22 (15.2) | 17 (23.9) | 5 (6.8) | |
| 2 | 1 (0.7) | 0 (0.0) | 1 (1.4) | |
| 3 | 56 (38.6) | 27 (38.0) | 29 (39.2) | |
| 4 | 5 (3.4) | 4 (5.6) | 1 (1.4) | |
| Not specified | 1 (0.7) | 0 (0.0) | 1 (1.4) | |
| Treatment history | 0.746 | |||
| Naive [n (%)] | 135 (93.1) | 67 (94.4) | 68 (91.9) | |
| Experienced [n (%)] | 10 (6.9) | 4 (5.6) | 6 (8.1) | |
| Treatment duration (weeks) [median (IQR)] | 8.0 (0.0) | 8.0 (0.0) | 8.0 (1.0) | 0.328 |
| 8 weeks [n (%)] | 115 (79.3) | 59 (83.1) | 56 (75.7) | |
| 12 weeks [n (%)] | 26 (17.9) | 9 (12.7) | 17 (23.0) | |
| 16 weeks [n (%)] | 4 (2.8) | 3 (4.2) | 1 (1.4) |
Abbreviations: SS, standard setting; DOT, directly observed therapy; OST, opioid substitution therapy; HIV, human immunodeficiency virus; IQR, interquartile range; HCV, hepatitis C virus.
a according to transient elastography (TE; n = 135) or APRI (n = 10; applied ULN for AST: 35 IU/L (female) and 50 IU/L (male)):
F0/F1: TE 0–7.1 kPa or APRI ≤ 0.5
F2: TE 7.2–9.4 kPa
F3: TE 9.5–12.4 kPa
F4: TE ≥ 12.5 or APRI > 1.5
b subtype not specified in n = 3 (2.1%)